Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Depreciation & Amortization (CF) (2016 - 2025)

Guided Therapeutics' Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $2000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) changed 0.0% year-over-year to $2000.0; the TTM value through Sep 2025 reached $9000.0, changed 0.0%, while the annual FY2024 figure was $9000.0, 0.0% changed from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $2000.0 at Guided Therapeutics, down from $3000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $3000.0 in Q4 2022 and bottomed at $1000.0 in Q3 2022.
  • The 4-year median for Depreciation & Amortization (CF) is $2000.0 (2023), against an average of $2230.8.
  • The largest YoY upside for Depreciation & Amortization (CF) was 100.0% in 2023 against a maximum downside of 33.33% in 2023.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $3000.0 in 2022, then tumbled by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Depreciation & Amortization (CF) are $2000.0 (Q3 2025), $3000.0 (Q2 2025), and $2000.0 (Q1 2025).